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Purpose/Objective: Advanced cervical cancer patients 
treated with (chemo-)radiation and MRI-guided adaptive 
brachytherapy (MR-IGABT) have high local control rates with 
acceptable treatment related morbidity. However, nodal 
recurrence is still a matter of concern. The aim of this study 
was to analyze the pattern of nodal failure in patients 
enrolled in the EMBRACE study (www.embracestudy.dk) and 
to explore potential predictive factors.  
Materials and Methods: Eight hundred and fifty-seven 
patients were treated at least 12 months prior to analysis. A 
number of 410 patients were lymph node negative and 406 
patients were lymph node positive at time of diagnosis. 
Lymphadenectomy or nodal debulking was allowed prior to 
(chemo-)radiation. All affected lymph nodes at time of 
external beam radiotherapy (EBRT) were treated within the 
elective field. Additionally, EBRT boosts aiming at the 
macroscopic nodal disease were allowed. 
Frequency analyses of anamnestic, gynaecological and 
histological information, MRI findings and treatment related 
factors were performed for all individual patients as well as 
for the patient groups with or without nodal failure. 
Multivariable analyses were used to explore potential 
predictive factors for nodal failure in all patients, and for the 
groups ‘node positive’ and ‘node negative’ lymph nodes at 
diagnosis. 
Results: During follow up (median 24 months, range, 3-60), 
62 of the 857 patients developed nodal failure (7%), with 70% 
detected within the first year after treatment. Two year 
survival was 65% and 93%, respectively, for patients with and 
without nodal failure. Nodal failure occurred in 5% of the 
patients without positive nodes and in 10% of the patients 
with positive nodes detected on CT, MRI, US, PET-CT or by 
histopathology at time of diagnosis. In the subgroup of 
patients with PET-CT positive or histopathology proven lymph 
nodes, 15% had a nodal failure. Positive nodes at diagnosis 
were mostly located in the pelvis, whereas recurrences 
mainly occurred in the para-aortic (PAO) region (Figure 1). 
Isolated PAO failures were seen in 35% of the patients with 
nodal failure.  
Cox proportional hazard analysis revealed positive lymph 
nodes at diagnosis, haemoglobin level < 6 mmol/L, white 
blood-cell count >10 x 109/L, and chemotherapy < 5 cycles as 
predictive factors for nodal failure. In the 'node positive' 
group FIGO stage was an additional predictive factor. In the 
'node negative' group tumour width appeared to be the only 
prognostic factor for nodal failure. 
Conclusions: The overall rate of nodal recurrences after 
(chemo-)radiation and MR-IGABT in advanced cervical cancer 
is low. The majority of nodal failures are located in the PAO 
region while affected lymph nodes at diagnosis are mostly 
seen in the pelvis. Two-year survival rates are significantly 
lower for patients with nodal failure. Lymph node 
involvement at diagnosis, haemoglobin level, white blood-cell 
count and chemotherapy are predictive for nodal failure. 
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Purpose/Objective: Combinations of local radiotherapy and 
immunotherapeutics have the potential to enhance local 
tumor control and to synergize in the induction of systemic 
antitumor immune responses. However, the optimal 
dose/fractionation regimens and optimal immunotherapy 
combinations still have to be defined. Here, we 
characterized the T cell responses induced by 
hypofractionated gamma-irradiation in a murine melanoma 
model and evaluated the extent of synergy of local tumor 
irradiation and PD-1 checkpoint-blocking or T cell-recruiting 
antibodies. PD-1 checkpoint-blocking antibodies enhance 
antitumor T cell responses; bispecific T cell-recruiting 
antibodies are capable of redirecting T cells to eradicate 
malignant cells. As monotherapy, both types of 
immunotherapeutics have recently shown dramatic efficacy 
in clinical trials in certain advanced malignancies, but it is 
not well understood to what extent they synergize with local 
tumor irradiation. 
Materials and Methods: We used a subcutaneous flank tumor 
model by employing B16 melanoma cells expressing the 
prototypic tumor stem cell marker CD133, which is also a 
marker for melanoma stem cells. An antagonistic antibody 
blocking the PD-1 immune checkpoint on T cells or a 
bispecific (CD133×CD3) antibody recruiting T cells to CD133+ 
tumor cells was administered after hypofractionated 
irradiation of either small (200–250 mm3) or large (500–750 
mm3) flank melanomas. Endpoints included tumor growth, 
overall survival, and immune infiltrate. 
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